- Home
- UAMY vs NGNE Comparison
UAMY vs NGNE Comparison
Compare UAMY & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAMY
- NGNE
- Stock Information
- Founded
- UAMY 1968
- NGNE 2003
- Country
- UAMY United States
- NGNE United States
- Employees
- UAMY N/A
- NGNE N/A
- Industry
- UAMY Metal Fabrications
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- UAMY Industrials
- NGNE Health Care
- Exchange
- UAMY Nasdaq
- NGNE Nasdaq
- Market Cap
- UAMY 251.9M
- NGNE 251.9M
- IPO Year
- UAMY N/A
- NGNE N/A
- Fundamental
- Price
- UAMY $2.22
- NGNE $20.09
- Analyst Decision
- UAMY Strong Buy
- NGNE Strong Buy
- Analyst Count
- UAMY 4
- NGNE 7
- Target Price
- UAMY $3.38
- NGNE $41.86
- AVG Volume (30 Days)
- UAMY 5.3M
- NGNE 239.4K
- Earning Date
- UAMY 08-08-2025
- NGNE 08-08-2025
- Dividend Yield
- UAMY N/A
- NGNE N/A
- EPS Growth
- UAMY N/A
- NGNE N/A
- EPS
- UAMY N/A
- NGNE N/A
- Revenue
- UAMY $18,865,900.00
- NGNE $925,000.00
- Revenue This Year
- UAMY $270.45
- NGNE N/A
- Revenue Next Year
- UAMY $104.06
- NGNE N/A
- P/E Ratio
- UAMY N/A
- NGNE N/A
- Revenue Growth
- UAMY 97.46
- NGNE N/A
- 52 Week Low
- UAMY $0.27
- NGNE $6.88
- 52 Week High
- UAMY $3.86
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- UAMY 39.44
- NGNE 57.57
- Support Level
- UAMY $2.71
- NGNE $14.65
- Resistance Level
- UAMY $2.71
- NGNE $18.21
- Average True Range (ATR)
- UAMY 0.24
- NGNE 1.84
- MACD
- UAMY -0.07
- NGNE 0.03
- Stochastic Oscillator
- UAMY 24.14
- NGNE 80.24
About UAMY United States Antimony Corporation
United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has four operating segments: United States Antimony, Mexican antimony, zeolite, and Precious metals. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.